CA2422245A1 - Methodes de traitement de troubles de la proliferation cellulaire - Google Patents

Methodes de traitement de troubles de la proliferation cellulaire Download PDF

Info

Publication number
CA2422245A1
CA2422245A1 CA002422245A CA2422245A CA2422245A1 CA 2422245 A1 CA2422245 A1 CA 2422245A1 CA 002422245 A CA002422245 A CA 002422245A CA 2422245 A CA2422245 A CA 2422245A CA 2422245 A1 CA2422245 A1 CA 2422245A1
Authority
CA
Canada
Prior art keywords
reovirus
mek
mammal
cells
neoplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422245A
Other languages
English (en)
Inventor
Matthew C. Coffey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncolytics Biotech Inc
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Priority to CA002422245A priority Critical patent/CA2422245A1/fr
Publication of CA2422245A1 publication Critical patent/CA2422245A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002422245A 2003-03-14 2003-03-14 Methodes de traitement de troubles de la proliferation cellulaire Abandoned CA2422245A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002422245A CA2422245A1 (fr) 2003-03-14 2003-03-14 Methodes de traitement de troubles de la proliferation cellulaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002422245A CA2422245A1 (fr) 2003-03-14 2003-03-14 Methodes de traitement de troubles de la proliferation cellulaire

Publications (1)

Publication Number Publication Date
CA2422245A1 true CA2422245A1 (fr) 2004-09-14

Family

ID=32968216

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422245A Abandoned CA2422245A1 (fr) 2003-03-14 2003-03-14 Methodes de traitement de troubles de la proliferation cellulaire

Country Status (1)

Country Link
CA (1) CA2422245A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations

Similar Documents

Publication Publication Date Title
US7815914B2 (en) Methods for the treatment of cellular proliferative disorders
US7799329B2 (en) Viruses for the treatment of cellular proliferative disorders
Hammel et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
AU776401C (en) Reovirus for the treatment of cellular proliferative disorders
AU2002212022A1 (en) Methods for the treatment of cellular proliferative disorders
AU2002212022A2 (en) Methods for the treatment of cellular proliferative disorders
CN1666105A (zh) 作为肿瘤的表型分析剂的肿瘤消解病毒
US7163678B2 (en) Reovirus for the treatment of ral-mediated cellular proliferative disorders
CA2422245A1 (fr) Methodes de traitement de troubles de la proliferation cellulaire
Wu et al. Loss of pS2 protein expression is an early event of intestinal‐type gastric cancer
US20050019308A1 (en) Oncolytic viruses for the treatment of neoplasms having activated PP2A or Rac
CA2411397C (fr) Reovirus pour le traitement de troubles de la proliferation cellulaire induits par ral
Redmond et al. A liquid-hybridization method for typing the Vp4 and Vp7 genes of bovine rotaviruses
KR20210130760A (ko) T 세포 레퍼토리 동역학 및 항암 바이러스 치료

Legal Events

Date Code Title Description
FZDE Dead